Indaptus Therapeutics, Inc. INDP
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Indaptus Therapeutics, Inc. (INDP) is a healthcare company listed in the US with a market value of about $422M.
Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is financial health (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -194%.
About Indaptus Therapeutics
Indaptus Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. It was profitable in 0 of the last 6 years in our data. Its share count rose by 227% over three years (dilution for shareholders).
Score: 0.6 / 5
Checks passed
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Net income | -$21M | -$15M | -$15M | -$14M | -$8M | -$4M |
| Free cash flow | — | — | — | — | -$11M | — |
| EPS (diluted) | $-21.58 | $-44.96 | $-51.24 | $-48.44 | $-52.92 | $-51.52 |
| Net margin | — | — | — | — | — | — |
| ROIC | -497.2% | -301.3% | -105.6% | -47.7% | -16.9% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Indaptus Therapeutics pay a dividend?
Not currently.
Is Indaptus Therapeutics a good stock to buy?
We do not give buy or sell advice. Indaptus Therapeutics scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.